• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Safety and efficacy study of Piclidenoson commenced for canine osteoarthritis treatment

November 24, 2021
dvm360 Staff
dvm360, dvm360 January 2022, Volume 53, Issue 1

With an excellent safety profile in human clinical trials, this drug may offer a much-needed solution for canine osteoarthritis as well.

Can-Fite BioPharma Ltd—a biotechnology company accelerating a pipeline of proprietary small molecule drugs that address inflammatory, cancer, and liver diseases—has announced its veterinary development and commercialization partner, Vetbiolix, has launched a safety and efficacy study of Piclidenoson for the treatment of canine osteoarthritis.

According to a company release,1 safety findings are expected in Q1 2022, and efficacy data is expected in Q4 2022. Piclidenoson has been extensively tested in human clinical trials with a favorable safety profile across more than 1,500 human patients.

“Based on Piclidenoson’s safety profile in humans and small animals, we expect similar excellent results in dogs. We are hopeful that Piclidenoson may also show efficacy in osteoarthritis and offer relief to millions of dogs and their families,” said Pnina Fishman, PhD, Can-Fite CEO, in the release.1

“Working with Vetbiolix for this veterinary indication, [we] aim to leverage our clinical pipeline to benefit animals while accelerating our path to commercialization through a capital-efficient strategy,” she added.

Piclidenoson is an oral drug with an excellent safety profile in human clinical trials and it may provide a necessary safe, effective treatment for canine osteoarthritis. The most frequently used existing treatments for this condition include oral non-steroidal anti-inflammatory drugs (NSAIDs) for pain control with substantial harmful side effects, and an injectable disease-modifying osteoarthritis drug (DMOAD) that targets the disease’s progress.1

Advertisement

About 20 to 25%2 of dogs have osteoarthritis—categorized by joint cartilage loss, joint capsule thickening, and new bone formation around the joint that results in limb dysfunction and pain. The canine osteoarthritis market is predicted to reach $3 billion by 2024.

Vetbiolix is responsible for all costs and development of Piclidenoson in the canine and feline osteoarthritis market, for which the company has the exclusive rights to Piclidenoson for 2 years under an option agreement. If the clinical studies provide positive results and Vetbiolix exercises its option to license from Can-Fite, then Vetbiolix will be required to pay Can-Fite upfront and milestone payments, along with royalties on sales upon regulatory approval for veterinary use.

Reference

  1. Can-Fite’s Piclidenoson commences clinical study for the treatment of canine osteoarthritis. News release. Can-Fite BioPharma Ltd. November 23, 2021. Accessed November 24, 2021. https://www.businesswire.com/news/home/20211123005715/en/Can-Fite%E2%80%99s-Piclidenoson-Commences-Clinical-Study-for-the-Treatment-of-Canine-Osteoarthritis
  2. Arthritis in dogs and cats. Saint Francis Animal Hospital. Accessed November 24, 2021. https://saintfrancisanimalhospital.com/2020/01/31/arthritis-in-dogs-and-cats/
download issueDownload Issue: dvm360 January 2022

Related Content:

Pain ManagementOrthopedicsMedicalClinicalRolesAssociatesdvm360 January 2022
Locoregional analgesia for pain management in veterinary medicine
Locoregional analgesia for pain management in veterinary medicine
Lyon College School of Veterinary Medicine names founding dean
Lyon College School of Veterinary Medicine names founding dean
Morris Animal Foundation funds study on environmental toxins and lymphoma
Morris Animal Foundation funds study on environmental toxins and lymphoma

Advertisement

Latest News

Locoregional analgesia for pain management in veterinary medicine

Outside toxicology experts can save pets’ lives

Lyon College School of Veterinary Medicine names founding dean

Morris Animal Foundation funds study on environmental toxins and lymphoma

View More Latest News
Advertisement